Barclays analyst Matt Miksic initiated coverage of Anteris Technologies (AVR) with an Overweight rating and $22 price target The timing for the company’s entry into transcatheter aortic valve replacement “could not look better,” the analyst tells investors in a research note. The firm says the market is now “deeply entrenched” between the preference for balloon-expandable valve and the need for hemodynamics in smaller valves. It believes Anteris ‘ DurAVR can provide balloon-expandable valve delivery for all valve sizes, and meet the growing demand for valve replacement.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVR:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue